Terrell Davis Partners With Teva Pharmaceuticals for Tardive Dyskinesia Awareness

NFL legend Terrell Davis has partnered with Teva Pharmaceuticals to launch a campaign aimed at increasing public awareness of Tardive Dyskinesia (TD), a neurological movement disorder. This initiative, titled "The Other TD," highlights the condition, which is often a side effect of medications used to treat mental health conditions. Davis, a two-time Super Bowl champion and former Denver Broncos running back, stated that his involvement stems from personal experience with mental health treatment, emphasizing the importance of open discussion about health struggles. He expressed that the diagnosis of someone close to him made the condition feel personal, as he recognized the possibility of experiencing similar side effects from his own prescribed medications.

Tardive Dyskinesia is characterized by involuntary, repetitive movements, often affecting the face, tongue, lips, or jaw, and can also involve limbs and the trunk. The campaign directs individuals experiencing potential symptoms to educational resources and encourages them to consult healthcare providers. For Teva Pharmaceuticals, this partnership aligns with its commercial interests, as the company manufactures Austedo, a leading prescription treatment for TD. Austedo represents a significant revenue stream for Teva, particularly as the company faces increased competition from generic alternatives for its older drug products. The collaboration underscores a broader trend in pharmaceutical marketing, shifting from traditional direct-to-consumer advertising of specific medications towards campaigns featuring trusted public figures, particularly athletes, who share personal health journeys.

This trend reflects a growing acceptance and visibility of mental health and neurological disorders within professional sports. Historically, athletes rarely discussed such issues publicly. However, prominent figures like former NFL offensive lineman Joe Barksdale and former wide receiver Brandon Marshall, who co-founded Project 375 to promote mental health awareness after his diagnosis of borderline personality disorder, have paved the way for more open conversations. Davis's participation in "The Other TD" campaign contributes to this evolving landscape, leveraging his platform to destigmatize neurological conditions and encourage proactive health management among patients and the general public. While Davis acknowledges compensation for his role in the Teva partnership, he maintains that his personal connection to mental health treatment was the primary motivator for his involvement.